Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      A Swedish Viewpoint

      Cardiology

      S. Karger AG

      Sweden, Cost, government intervention, Drug utilization

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In Sweden the government owns, operates, and finances nearly all health care; therefore, intervention by the government is virtually total. Until recently, government intervention in cardiovascular disease was mainly by allocation of resources through budgets to different hospital departments, based on the advice of expert groups. However, this form of intervention has become ineffective over the last few years as economic conditions have deteriorated and health care spending ceased to grow. Instead, interventions aimed at containing costs and improving the efficiency of health care have now been implemented. The important question in government intervention in health care is whether it will be compatible with clinical and therapeutic freedom and with continued progress in medical research. In the future regulations must be developed with a greater knowledge about the interaction between economic and medical factors in health care in order to provide clinical and therapeutic freedom whilst allowing continued progress in medical research.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-6144-0
          978-3-318-01954-4
          0008-6312
          1421-9751
          1994
          1994
          18 November 2008
          : 85
          : Suppl 1
          : 90-95
          Affiliations
          Stockholm School of Economics, Stockholm, Sweden
          Article
          176767 Cardiology 1994;85:90–95
          10.1159/000176767
          7743541
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Session IV: Government Intervention in Cardiovascular Disease – Help or Hindrance?

          Comments

          Comment on this article